BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Kallikrein-related peptidase 5 (KLK5); KLK7; KLK14; suppression of tumorigenicity 14 (ST14; matriptase)

February 19, 2015 8:00 AM UTC

In vitro and mouse studies have identified coumarin-3-carboxylate-based protease inhibitors that could help treat skin diseases such as Netherton syndrome, which is characterized by high levels of Kal...